TriangleMAGENTA (NCT07032714)
MAGENTA trial for Relapsed or Refractory Multiple Myeloma (NCT07032714). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with multiple myeloma that has come back or not responded to treatment.
The idea: combine two drugs. Mezigdomide, a pill taken once a day, and talquetamab, an antibody injected under the skin, with the dose stepped up at the start. Dexamethasone, a steroid pill, is given with them. Two groups try different orders for starting the drugs.
The study looks for the recommended dose and schedule, and the effects on the cancer.
This phase 1 study plans 25 patients. At Massachusetts General Hospital in Boston, Andrew Yee leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.